Beta Bionics (BBNX) investor relations material

Executive summary

• Q2 2026 net sales reached $32.0 million, up 38% year-over-year, driven by new patient starts, increased single-use product sales, and strong growth in both DME and PBP channels.

• Gross margin improved to 59% (up 524 basis points year-over-year), reflecting higher production scale, strong recurring revenue, and lower warranty rates.

• Operating expenses rose 37% year-over-year to $44.5 million, mainly due to sales force expansion and R&D investments.

• Net loss for Q2 2026 was $23.4 million, reflecting higher operating expenses and ongoing investment in growth.

• The company advanced its innovation pipeline, including the Mint patch pump and bihormonal system, and made significant progress on FDA warning letter remediation.

Financial highlights

• Q2 2026 revenue grew 38% year-over-year to $32.0 million, with gross profit of $18.9 million and gross margin at 59%.

• Adjusted EBITDA for Q2 2026 was negative $17.7 million, reflecting continued investment in growth.

• Net loss per share for Q2 2026 was $(0.53).

• Cash, cash equivalents, and investments totaled $225.2 million as of June 30, 2026.

• Six-month net sales reached $59.6 million, up 46% year-over-year.

Outlook and guidance

• Full-year 2026 revenue guidance reiterated at $131–$136 million.

• Gross margin outlook raised to 58.5%–59.5% for the year.

• Expect 37%–39% of new patient starts to be reimbursed through the PBP channel.

• Mint patch pump commercial launch targeted for end of Q2 2027, pending FDA clearance.

• Existing cash and investments expected to fund operations through the first half of 2028.